{"title":"The effect of COVID-19 on oncology pharmacy services","authors":"M. Crul, A. Boşnak, A. Astier, K. Meier","doi":"10.1097/OP9.0000000000000027","DOIUrl":null,"url":null,"abstract":"Introduction:The COVID-19 pandemic has been felt in all areas of health care. We performed a weekly survey amongst the members of the European Society of Oncology Pharmacy (ESOP) to better understand its effects and how they evolved over time. We specifically studied alterations in the care for patients with cancer as well as in the work of oncology pharmacists. Method(s):An online survey was developed by ESOP to compile data about the effects of COVID-19 on the work practices of professionals working in the field of oncology pharmacy. The survey was distributed electronically on a weekly basis from April 6thto June 28th. Result(s):A total of 1146 responses were gathered from respondents in 60 different countries. At any given time point, between 25% and 38% of the respondents had staff infected with COVID-19. In total, 29% of hospital pharmacists reported shortages of drugs necessary for the treatment of COVID-19 patients, and almost 50% also faced shortages of drugs necessary for the treatment of cancer patients. In addition, the majority of hospital pharmacists reported a decrease in planned surgery for oncology patients, as well as a decrease in the amount of chemotherapy preparations. Community pharmacists faced shortages of personal protective equipment in 40% of cases and shortages of drugs in 60%. Conclusion(s):The work of oncology pharmacists both in the clinical setting as well as in the community has been effected profoundly by the COVID-19 pandemic.Copyright © 2021 Lippincott Williams and Wilkins. All rights reserved.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Oncology Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/OP9.0000000000000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3
新冠肺炎疫情对肿瘤药学服务的影响
导言:COVID-19大流行已影响到卫生保健的所有领域。我们在欧洲肿瘤药学学会(ESOP)的成员中进行了每周一次的调查,以更好地了解它的效果以及它们是如何随着时间的推移而演变的。我们专门研究了对癌症患者的护理以及肿瘤药剂师工作的改变。方法:ESOP开展了一项在线调查,收集有关COVID-19对肿瘤药学领域专业人员工作实践影响的数据。该调查从4月6日至6月28日每周以电子方式发布一次。结果:共收集了来自60个不同国家的1146份回复。在任何给定的时间点,25%至38%的受访者有员工感染了COVID-19。总体而言,29%的医院药剂师报告治疗COVID-19患者所需药物短缺,近50%的医院药剂师还面临治疗癌症患者所需药物短缺的问题。此外,大多数医院药剂师报告了肿瘤患者计划手术的减少,以及化疗制剂的数量减少。社区药剂师面临个人防护装备短缺的情况占40%,药品短缺的情况占60%。结论:新冠肺炎疫情对肿瘤药师的临床和社区工作都产生了深刻影响。版权所有©2021 Lippincott Williams and Wilkins。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。